The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

What is Neuromodulation?

Breaking News Share

Company's Neurostimulator Receives CE Mark for MRI-Conditional Body Scans

Nov. 16, 2017 - Nevro Corp. announced receiving CE mark approval for MRI conditional use of its high-frequency spinal cord stimulator for chronic pain. Previously the device had CE mark for head and extremity MRI scans. The new approval applies retroactively to patients already implanted with the device. (Mass Device)

Startup Focuses on Advancing Neuroprosthetic Capabilities

Nov. 16, 2017 - An article describes the efforts of the startup Kernel to develop ambitious neuroprosthetic capabilities to sense and stimulate through brain-computer interfaces. (Wired)

FDA Approves Percutaneous Nerve Field Stimulation Device for Opioid Addiction Withdrawal Treatment

Nov. 15, 2017 - A noninvasive percutaneous nerve field device worn behind the ear and previously cleared by the U.S. FDA for acupuncture indications in 2014 has received approval for use by prescription to treat acute symptoms of opioid withdrawal. The treatment is intended to be a transitional aid for medically assisted weaning from opioid addiction. The electro auricular device was studied in 73 patients, who reported a 31% reduction in such symptoms as wearing, gastrointestinal upset, agitation, insomnia and joint pain after 30 minutes of stimulation. In a news release, the device developer, Innovative Health Solutions, Inc., said withdrawal symptoms were reduced by 84.6% in at least 60 minutes of treatment with the single-use device. The company posted a brief video explaining the function of their NSS-2 Bridge device. (MD Magazine)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM